ACOT2

Across TCGA pan-cancer cohorts, ACOT2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ACOT2 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ACOT2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ACOT2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, HNSC, and LSCC are the cancer types where ACOT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.996	0.797	.003	27	view →
HNSC	DFS	Quartile	IV	0.987	0.615	.016	4	view →
LSCC	DFS	Tertile	All	0.887	1.000	.026	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ACOT2–CCRCC (OS)

Open the CCRCC breakdown →